International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) studyInternal Medicine and Systemic Diseases Unit, University Hospital Centre Dijon, Dijon, France.
Unidade de Imunologia Clínica – Unidade Local de Saúde Santo António; UMIB - Unit for Multidisciplinary Research in Biomedicine, ICBAS - School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal; ITR - Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal.
Division of Rheumatology, Mayo Clinic Minnesota, Rochester Minnesota, USA.
UDAI – Autoimmune Diseases and Immunology Unit, Internal Medicine Department, ULS Tâmega e Sousa, Penafiel, Portugal; Unit for Multidisciplinary Research in Biomedicine (UMIB), School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal; i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Rheumatology Section, Hospital italiano de Buenos Aires, Buenos Aires, Argentina.
Department of Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.
School of Infection and Immunity, University of Glasgow, Glasgow, UK.
Departmento of Orthopedics, Rheumatology and Traumatology-Universidade Estadual de Campinas, Campinas, Brazil.
School of Medicine, University of Zagreb, Zagreb, Croatia; Division of Clinical Immunology and Rheumatology, Referral Centre for SLE and Related Diseases, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.
Johns Hopkins University School of Medicine, Baltimore Maryland, USA.
Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy.
Feinstein Institutes for Medical Research, Northwell Health System, Manhasset New York, USA.
Rheumatology Division, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Rumah Sakit Universitas Indonesia, Depok, Indonesia.
Division of Rheumatology, Department of Internal Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Rheumatology and Clinical Immunology Unit, Attikon University Hospital, National Kapodistrian University of Athens Medical School, Athens, Greece.
Department of Neuropsychology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Division of Rheumatology, Hospital for Sick Children, Toronto Ontario, Canada; Neurosciences and Mental Health Program, SickKids Research Institute, Toronto Ontario, Canada; Temerty Faculty of Medicine, University of Toronto, Toronto Ontario, Canada.
Department of Neuropsychology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
School of Clinical Sciences, Monash University, Melbourne Victoria, Australia.
Lupus Europe, Brussels, Belgium.
Center for Research and Social Intervention (CIS-Iscte), ISCTE-University Institute of Lisbon, Lisbon, Portugal.
Lupus Europe, Brussels, Belgium.
Lupus Europe, Brussels, Belgium.
Lupus Program at University Health Network, Schroeder Arthritis Institute, Krembil Research Institute, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.
Show others and affiliations
2026 (English)In: Lupus Science and Medicine, E-ISSN 2053-8790, Vol. 13, no 2, article id e002148Article in journal (Refereed) Published
Abstract [en]
Introduction: Cognitive symptoms such as 'brain fog' are frequent and disabling in patients with SLE. We aimed to develop and validate the Lupus Brain Fog Severity Scale (LBFSS), the first patient-reported outcome measure (PROM) for cognitive symptoms in SLE.
Methods: The LBFSS was developed using a multi-step international approach involving healthcare professionals and patients with SLE. Patients provided free-text descriptions of brain fog, generating candidate domains through thematic analysis (step 1). Domains were rated for relevance (step 2) and those retained converted into self-assessable items (step 3). The pilot LBFSS was iteratively refined (step 4). The finalised LBFSS was validated (step 5) in a large international SLE cohort. Psychometric evaluation included internal consistency, exploratory factor analysis and assessment of construct, convergent, known-groups and criterion-related validity.
Results: In step 1, 147 SLE participants across 39 countries generated 21 domains for cognitive symptoms, of which 13 were retained in consensus (step 2), converted into self-assessable items (step 3) and iteratively refined using patient and physician feedback. In step 5, validation of the LBFSS instrument in 378 patients from 36 countries demonstrated high internal consistency (Cronbach's alpha=0.95) and a unidimensional structure explaining 62.2% of variance. LBFSS scores were significantly higher in participants reporting brain fog (p<0.0001), confirming known-group validity. Construct validity was supported by significant correlations with functional impact and symptom severity (rho=0.46-0.65, p<0.0001), strong convergent validity with the Perceived Deficits Questionnaire-20 (rho=0.84, p<0.0001) while the discriminative performance for presence versus absence of self-reported brain fog was high (area under the curve=0.85).
Conclusion: The LBFSS is a new, valid and feasible PROM to assess brain fog and cognitive symptoms in SLE.
Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2026. Vol. 13, no 2, article id e002148
Keywords [en]
Systemic Lupus Erythematosus, Autoimmune Diseases, Health-Related Quality Of Life, Patient Reported Outcome Measures
National Category
Rheumatology
Identifiers
URN: urn:nbn:se:oru:diva-130202DOI: 10.1136/lupus-2026-002148ISI: 001819457800001PubMedID: 42442803OAI: oai:DiVA.org:oru-130202DiVA, id: diva2:2087929
2026-07-232026-07-232026-08-07Bibliographically approved